{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-079749","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.503696+00:00","generated_at":"2026-05-20T04:02:30.720234+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Plus Therapeutics Q1 net loss $17.4M; cash jumps to $9.9M on $15M financing and grants","bullets":["Cash balance $9.9M at Mar 31, 2025 vs $0.1M at Dec 31, 2024; raised $15M private placement and $2M grant advance.","Net loss $17.4M ($1.19/share) vs $3.3M ($0.75/share) in Q1 2024; operating loss $3.5M vs $3.3M.","Completed ReSPECT-LM Phase 1 dose trial; FDA Orphan Drug Designation for REYOBIQ for leptomeningeal metastases in lung cancer.","Published Phase 1 REYOBIQ data in Nature Communications: >100 Gy dose group median OS 17 months, double standard of care.","Added board member Kyle Guse; management hires: Dr. Rosol (CDO), Bradley (CNSide President), Stein (Medical Director)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-079749","json":"https://secwatch.observer/filing/0000950170-25-079749.json","markdown":"https://secwatch.observer/filing/0000950170-25-079749.md","text":"https://secwatch.observer/filing/0000950170-25-079749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025079749/0000950170-25-079749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025079749/pstv-20250530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:02:30.720234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}